IBD has a prevalence of ~ 0.2% of the Western population. In the United States alone, there are more than a million diagnosed IBD patients. IBD results in enormous suffering and health-care costs. In addition, repeated GI inflammation puts individuals at an increased risk of developing colon cancer. Although there are currently a variety of clinical treatments to alleviate the symptoms of IBD patients, and increasing therapeutic options are being developed as a result of ongoing research, there is no cure for the diseases. In addition, long-term usage of some of the current therapies, such as glucocorticoids and immunosuppressive agents, can be associated with serious side-effects. Progress has been made in recent years in understanding the pathological mechanisms of IBD, particularly in the search of IBD susceptibility genes. However, due to the extreme complexity of the diseases, there is still a long way ahead in elucidating detailed molecular mechanisms of IBD pathogenesis and identifying more effective therapeutic targets. Therefore, it is the goal of this research study to discover biomarkers and protein factors involved in the pathogenesis of IBD which may pave the way for the identification of more effective therapeutic targets.